![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GeoVax Labs Inc | NASDAQ:GOVXW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0381 | 71.62% | 0.0913 | 0.09 | 0.1369 | 0.60 | 0.0606 | 0.22 | 542,759 | 00:26:44 |
Presentation Details:Presenter: David Dodd, Chairman & CEODate/Time: January 8, 2023, 2:30 pm PSTLocation: Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CARegistration: Biotech Showcase
A live webcast of the presentation will be available here. A replay will be available approximately 2 hours after the presentation and accessible for three months.
Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
Company Contact: | Investor Relations Contact: | Media Contact: | ||
info@geovax.com | paige.kelly@sternir.com | sr@roberts-communications.com | ||
678-384-7220 | 212-698-8699 | 202-779-0929 | ||
1 Year GeoVax Labs Chart |
1 Month GeoVax Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions